Navigation Links
Robert Haynes To Lead Licensing As VR Laboratories' Senior Vice President Product Introduction And Licensing
Date:11/14/2012

BONITA SPRINGS, Fla., Nov. 14, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced the appointment of Robert Haynes as Senior Vice President, Product Introduction and Licensing. Haynes brings more than 25 years of management and executive experience in pharmaceutical and biotechnology product development, partnering, and global commercialization.  Most recently, Haynes led the Alliance Management and New Product Planning departments at Human Genome Sciences (HGS). At HGS Haynes also led the development and global commercialization of the company's lead product - Benlysta®  - taking it from discovery through clinical development and successful commercialization around the world as the first new therapy approved for lupus in over 50 years. In addition to Benlysta Mr. Haynes has held leadership roles for numerous successful brands including Strattera®, Evista®, Axid®, Prozac®, and Ceclor®.

(Photo: http://photos.prnewswire.com/prnh/20121114/CG13570)

"Robert brings extensive experience in the pharmaceutical and biotechnology industries to VR and we look forward to his leadership in advancing our extensive pipeline internally and with partners across the globe," says Jeff Kottkamp, CEO of VR Laboratories. "As an innovative natural products company, we will benefit from his experience, developing, launching, commercializing, and partnering assets in all stages across many different therapeutic areas."

Haynes' background includes a wide variety of commercial management positions in both the pharmaceutical and biotechnology industries. This includes business development and licensing, strategic marketing, new product development, global brand and portfolio management, market research, and sales. He began his career with Eli Lilly and company in 1988 following receiving his Masters of Business Administration degree from the Owen Graduate School of Management at Vanderbilt University. In addition, he holds a Bachelors degree in Biological Science from DePauw University. 

"I look forward to continuing to develop and commercialize innovative medicines in the rapidly growing natural product industry," says Haynes. "VR Laboratories has great momentum as it looks to grow its business and expand its global presence. I'm excited to be joining VR's talented team and look forward to working with them to capitalize on their industry leading technology to build a successful fully integrated business."

About VR Laboratories

VR Laboratories is an innovative natural products company formed by industry professionals in 2010 to be the leading global formulator and producer of natural products.  VR Laboratories utilizes industry-changing proprietary technology to create, produce and market "First in Class" condition specific botanical based consumer health and wellness products, FDA-approved botanical pharmaceuticals and medicines and proprietary ingredients for medicinal and functional foods and beverages. The company utilizes a proprietary technology platform, which has fully developed more than 1,000 medicinal and functional ingredients.  VR Laboratories is headquartered in Bonita Springs, Florida.


'/>"/>
SOURCE VR Laboratories www.vr-laboratories.com
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
2. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Robert Farrell Joins Bionovos Board of Directors
5. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
6. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
7. Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
8. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
9. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
10. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
11. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... The Energy and Resources Institute ... producing mycorrhizae. The Centre for Mycorrhizal Research at TERI ... and developed a technology that eventually produces mycorrhizae based ... ... The TERI facility has a production capacity of over ...
(Date:1/12/2017)... 12, 2017 The report "Direct-Fed Microbials Market by Type (Lactic Acid ... Liquid), and Region - Global Forecast to 2022", published by MarketsandMarkets, the global ... projected to reach USD 1,399.6 Million by 2022, at a CAGR of 6.96% ... ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Ovation Fertility™ Genetics ... reliable preimplantation genetic screening (PGS). , “Our genetics and IVF teams are recognized ... Genetics Scientific Director Amy Jones, M.S., ELD (ABB) , who has worked ...
(Date:1/11/2017)... 11, 2017  Brian Mehling, M.D., world-renowned stem cell ... Horizon International (BHI), will be attending the 47th Annual ... from January 17-20, 2017. This will be Dr. ... The theme of this year,s forum is Responsive and ... will address strategies for fostering greater social inclusion and ...
Breaking Biology Technology:
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
Breaking Biology News(10 mins):